These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

646 related articles for article (PubMed ID: 33516133)

  • 1. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
    Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
    Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review and network meta-analysis (NMA) for cladribine tablets in achieving sustained disability improvement (SDI) in multiple sclerosis.
    Piasecka-Stryczyńska K; Kaczyński Ł; Rolka M; Homa M; Staśkiewicz W; Paczwa P; Wójcik R; Kaczor MP; Rejdak K
    Neurol Neurochir Pol; 2022; 56(6):480-489. PubMed ID: 36421066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis.
    Siddiqui MK; Khurana IS; Budhia S; Hettle R; Harty G; Wong SL
    Curr Med Res Opin; 2018 Aug; 34(8):1361-1371. PubMed ID: 29149804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
    J Neurol; 2020 Jul; 267(7):2090-2100. PubMed ID: 32246251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
    Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL
    Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
    Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
    Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
    Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL
    Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
    Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the comparative efficacy of cladribine tablets versus alternative disease modifying treatments in active relapsing-remitting multiple sclerosis: adjusting for patient characteristics using meta-regression and matching-adjusted indirect treatment comparison approaches.
    Berardi A; Siddiqui MK; Treharne C; Harty G; Wong SL
    Curr Med Res Opin; 2019 Aug; 35(8):1371-1378. PubMed ID: 30786783
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative effectiveness of dimethyl fumarate in multiple sclerosis.
    Bosco-Lévy P; Debouverie M; Brochet B; Guillemin F; Louapre C; Maillart E; Heinzlef O; Lignot S; Diez P; Abouelfath A; Lassalle R; Blin P; Droz-Perroteau C
    Br J Clin Pharmacol; 2022 Mar; 88(3):1268-1278. PubMed ID: 34505304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
    Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan KW; Rieckmann P; Comi G; Dangond F; Hicking C; Vermersch P
    Mult Scler; 2019 May; 25(6):819-827. PubMed ID: 29716436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
    Spelman T; Ozakbas S; Alroughani R; Terzi M; Hodgkinson S; Laureys G; Kalincik T; Van Der Walt A; Yamout B; Lechner-Scott J; Soysal A; Kuhle J; Sanchez-Menoyo JL; Blanco Morgado Y; Spitaleri D; van Pesch V; Horakova D; Ampapa R; Patti F; Macdonell R; Al-Asmi A; Gerlach O; Oh J; Altintas A; Tundia N; Wong SL; Butzkueven H
    Mult Scler; 2023 Feb; 29(2):221-235. PubMed ID: 36433775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry.
    Braune S; Grimm S; van Hövell P; Freudensprung U; Pellegrini F; Hyde R; Bergmann A;
    J Neurol; 2018 Dec; 265(12):2980-2992. PubMed ID: 30327931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
    Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Keller B; Jack D; Vermersch P
    Adv Ther; 2021 Sep; 38(9):4975-4985. PubMed ID: 34370275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substantial and comparable suppression of disease activity following early initiation of cladribine tablets, ocrelizumab or alemtuzumab as first pharmacologic treatment for relapsing multiple sclerosis: A real world study.
    Alroughani R; Al-Hashel J; Ahmed SF
    Clin Neurol Neurosurg; 2024 May; 240():108249. PubMed ID: 38513425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
    Hettle R; Harty G; Wong SL
    J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
    Giovannoni G; Singer BA; Issard D; Jack D; Vermersch P
    Mult Scler; 2022 Jul; 28(8):1219-1228. PubMed ID: 34634968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
    Pinheiro B; Guerreiro R; Costa J; Miguel LS
    J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis:
    Vermersch P; Galazka A; Dangond F; Damian D; Wong SL; Jack D; Harty G
    Curr Med Res Opin; 2021 Mar; 37(3):459-464. PubMed ID: 33331183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cladribine Tablets for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Lambe T; Duarte R; Mahon J; Nevitt S; Greenhalgh J; Boland A; Beale S; Kotas E; McEntee J; Pomeroy I
    Pharmacoeconomics; 2019 Mar; 37(3):345-357. PubMed ID: 30328051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.